NPY and Huntington disease: Therefore, IN-NPY has been explored in preclinical studies using an R6/2 mouse model of HD to further elucidate its role in HD pathology, with 4 week old mice receiving either IN-NPY, IN-NPY Y2 receptor agonist (NPY13–36), or saline 5 days a week for a period of 8 weeks.